Kihealth, Inc., a precision diagnostics company focused on disease interception and metabolic health, today announced the launch of Beta Intercept™, the latest version of its proprietary beta-cell ...

Precision BioLogic originally developed CRYOcheck Chromogenic Factor VIII in response to a growing demand for chromogenic assays 1. Launched in 2020, it was the first commercially available, ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...

The US Food and Drug Administration (FDA) on Wednesday finalized guidance to help industry develop and validate immune assays for the assessment of the immunogenicity of therapeutic protein products ...

The EXONERATE assay has demonstrated that it can predict outcomes and monitor resistance in colorectal cancer patients treated with EGFR inhibitors.

Next-generation sequencing (NGS) has become increasingly popular with testing laboratories allowing them to obtain more data in less time and with minimal input. In this webinar we will explore the ...

Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan–Treated Human Epidermal Growth Factor Receptor 2–Positive ...

BD-pTau 217 is a refined biomarker which enhances Alzheimer’s specificity while retaining the strengths of plasma pTau 217.